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ScienceDirectSince introducing the concept of epigenome-wide association
studies (EWAS) in 2011, there has been a vast increase in the
number of published EWAS studies in common diseases,
including in cancer. These studies have increased our
understanding of epigenetic events underlying carcinogenesis
and have enabled the discovery of cancer-specific methylation
biomarkers. In this mini-review, we have focused on the state of
the art in EWAS applied to cell-free circulating DNA for
epigenetic biomarker discovery in cancer and discussed
associated technical advances and challenges, and our
expectations for the future of the field.
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Introduction
The epigenome represents the compendium of (mitoti-
cally) heritable molecular changes, independent of altera-
tions in the DNA sequence that holistically regulate (in
concert with other factors) the mode of expression of the
information encoded in the DNA sequence, hence deter-
mining the cellular phenotype [1]. Epigenetic marks
include DNA methylation, histone modifications and
variants as well gene expression regulation by ncRNAs.
DNA methylation is one of the most important epigenetic
modifications in eukaryotes necessary for cellular differ-
entiation, with each cell type having a unique methyla-
tion profile. Environmental exposures, age-related
changes and those induced by injury and inflammation,
or mutations in epigenome-regulating genes, leave their
mark on the methylome creating a distinctive footprint.
Analogous to genome-wide association studies (GWAS),
epigenome-wide studies (EWAS) are designed to identifyCurrent Opinion in Genetics & Development 2017, 42:48–55 associations of epigenetic marks with a specific pheno-
type (trait, condition or a disease) using a variety of array-
or sequencing-based profiling technologies [2]. The most
commonly studied epigenetic mark is DNA methylation
of 5-methylcytosine in CpG context. DNA methylation
plays a crucial role in gene regulation of many oncogenes
and tumour suppressor genes, and aberrant DNA meth-
ylation of both individual gene promoters and on a
genome-wide scale has been heavily implicated in cancer
initiation and progression [3,4].
Hypermethylation of promoter CpG islands may induce
epigenetic silencing of individual tumour suppressor
genes while global hypomethylation contributes to
tumourigenesis through the promotion of genomic insta-
bility and activation of oncogenes. It has been well
documented that specific epigenetic changes, such as
MGMT promoter hypermethylation in glioblastoma, or
global hypermethylation in bladder cancer, have been
associated with sensitivity/resistance to chemotherapeu-
tic drugs [5–7]. Alterations in DNA methylation patterns
were shown to be an early feature in cancer development,
and unlike mutations, specific epimutations are highly
prevalent within tumour types [8–11]. Pronounced intra-
tumour heterogeneity of promoter DNA methylation has
been documented in a variety of tumours, and recent
studies have demonstrated a positive correlation between
the extent of genome-wide DNA methylation heteroge-
neity and adverse patient outcome [12–14]. Altogether,
these findings have spurred research into the potential
use of specific DNA methylation alterations as cancer
biomarkers for diagnosis, prognosis and prediction of
therapy response, and early detection [15–17].
Cancer EWAS and biomarkers
The scope for the discovery of novel DNA methylation
biomarkers has greatly expanded due to the evolution of
new technologies enabling a transition from candidate-
gene approaches to genome-wide studies based on micro-
array and sequencing methods interrogating hundreds of
thousands of CpG loci, and ultimately to bisulfite
sequencing of the whole genome or a selected fraction
of the genome. EWAS have provided a systematic insight
into both environmental (such as diet and smoking), and
intrinsic factors that result in altered DNA methylation
profiles. Although the causal relationship cannot be
inferred with certainty from EWAS, DNA methylation
marks strongly associated with the phenotype of interest
can, nevertheless, be useful as cancer biomarkers [15,18].www.sciencedirect.com
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Infinium Bead Array (‘450 K array’) and methylation pull-
down sequencing assays, the number of EWAS studies
aimed at identifying and validating specific DNA meth-
ylation changes associated with cancer initiation, specific
subtypes, prognosis or drug response published each year
has tripled [17]. Many DNA methylation biomarkers with
diagnostic, prognostic and predictive power are already in
clinical trials or the clinical setting for cancer [19]. One
such success story for DNA methylation biomarker devel-
opment, with rapid translation from bench to bedside, is
the methylation of the SEPT9 promoter as implemented
in a blood-based test for colorectal cancer (CRC) screen-
ing [20]. Following extensive validation in prospective
clinical trials, the SEPT9 test has been commercially
marketed as Epi proColon (Epigenomics AG) and been
made available in several European countries, China and
USA where it has been recently approved by the US Food
and Drug Administration (FDA).
DNA sources for EWAS
Given the robustness of DNA methylation during cell
isolation and processing, DNA derived from almost any
tissue type or bodily fluid can be used for DNA meth-
ylation analysis, provided there is enough input material
for the chosen assay. Figure 1 illustrates the most com-
mon cell-based and cell-free DNA sources used for
EWAS and why. Although it is desirable to measure
disease-associated DNA methylation biomarkers in a
disease-relevant tissue or primary cell type, surrogate
tissues such as whole blood may be used if the biomarker
is tightly associated with the phenotype of interest either
directly or indirectly. Whole blood has been commonlyFigure 1
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Cell-based and cell-free DNA sources for epigenome-wide association
studies (EWAS). DNA can be derived from whole blood (wb), affected
tissue (at), purified primary cells (pc) and biofluids, including blood
plasma or serum, with (cf) referring to all circulating cell-free DNA and
(ct) to circulating cell-free tumour DNA.
www.sciencedirect.com used as a surrogate tissue of choice for many EWAS
studies performed to date despite limitations in detecting
tissue-specific alterations and the requirement to correct
for cell composition heterogeneity reviewed in [21,22]. A
notable early example of a blood-based EWAS applying
cell composition correction is a study by Liu et al. in which
they identified four CpG loci in the major histocompati-
bility complex (MHC) cluster associated with rheumatoid
arthritis by analysing 354 cases and 337 healthy controls
using the 450 K array platform [23]. Other types of tissues,
including solid tumour biopsies, have also been success-
fully used to identify biomarkers as well as mechanisti-
cally relevant differentially methylated positions (DMPs)
and regions (DMRs), in lung cancer [24], osteosarcoma
[25], Wilms tumour [26], penile carcinoma [27], glioblas-
toma [28], neuroblastoma [29] and cervical carcinoma [30]
to name but a few recent studies. However, for successful
discovery of biomarkers based on comparing (preferably
matched) tumour and normal tissue samples, and subse-
quent translation to a blood-based test suitable for a
clinical environment, it is important to include whole
blood as a control tissue and/or screen the biomarker
against an appropriate database such as MARMAL-AID
[31,32]. This will ensure that selected cancer-specific
biomarkers will not be or only be minimally confounded
by cell composition effects.
Liquid biopsies for biomarker discovery
Because of their invasive nature, tumour biopsies cannot
always be performed in the clinical setting and; addition-
ally, they are liable to sampling bias owing to the hetero-
geneous nature of solid tumours. To overcome these
limitations, liquid biopsies are increasingly being used
as a minimally invasive alternative and more comprehen-
sive capture of tumour heterogeneity [33]. For that,
circulating tumour (ctDNA) or cell-free DNA (cfDNA)
isolated from different biofluids, such as plasma, serum,
urine or saliva can be used for biomarker discovery in the
context of tissue [34,35] and tumour [36,37] dynamics,
including tissue-specific cell death as well as tumour load,
progression and evolution (Figure 1).
Cell-free DNA is highly fragmented to a mean length of
only around 180 base pairs. Components of cfDNA
include DNA shed by normal cells undergoing apoptosis
in healthy individuals, but both necrosis and apoptosis of
tumour cells, disseminated tumour cells (DTC), and
active secretion of DNA by living cells contribute to
ctDNA in cancer patients. Although ctDNA makes up
less than 1% of total cfDNA content, it can be distin-
guished from normal cfDNA by the presence of tumour
specific chromosomal, genetic or epigenetic alterations
[36,38,39].
The presence of detectable ctDNA was determined in
early stage solid tumours across different cancer types,
albeit at low quantities [40], and several studiesCurrent Opinion in Genetics & Development 2017, 42:48–55
50 Cancer genomicsdemonstrated the utility of ctDNA for monitoring tumour
dynamics during treatment in patients with advanced
disease. Exemplar proof-of-principle efforts include a
study on metastatic breast cancer comparing the utility
of targeted sequencing of ctDNA to serum cancer antigen
15-3 (CA15-3) and circulating tumour cells (CTCs) to
measure treatment response [41], and a study by Murtaza
and colleagues applying exome sequencing to track
tumour evolution of breast, ovarian and lung cancers in
response to therapy [42]. In contrast, most of the studies
looking at cfDNA methylation associated with tumour
stage, prognosis and response to therapy performed to
date were based on candidate-gene approaches [43–47].
Studies based on genome-wide methylation profiling
of cfDNA remain scarce [48,49,50,51] due to techni-
cal challenges including minute amounts of starting
material, procedural losses during sample processing,
DNA extraction, bisulfite conversion and library prepara-
tion (Figure 2).
Technical challenges
Although there is a plethora of available methods for
genome-wide DNA methylation profiling, including theFigure 2
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Current Opinion in Genetics & Development 2017, 42:48–55 use of methylation-specific restriction enzymes, affinity
enrichment or bisulfite conversion in combination with
microarray or sequencing; these methods differ not only
in their coverage and resolution (ranging from few 100s to
1 bp), but also requiredifferent amounts of startingmaterial
[52,53]. The gold standard method for genome-wide
interrogation of DNA methylation at a single base pair
resolution with a digital readout is bisulfite sequencing
(BS-seq) [54,55]. Here, we discuss the critical determinants
for applying high-throughput genome-wide BS-seq to
EWAS for cancer biomarker discovery in liquid biopsies
(Figure 2).
Firstly, the choice of biofluid is of significant importance,
and should be selected not only in relation to the biology
of the disease (for instance, urine for bladder cancer,
saliva for oral cancer, etc.), but also taking into consider-
ation the composition of the sample. For example, even
though blood serum contains higher concentrations
of cfDNA per ml than plasma, it was demonstrated that
large fraction of it originates from lysed lymphocytes
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uencing in liquid biopsies. The biological or clinical question
 determines the source of potential gDNA contamination of liquid
asma, serum, urine, cerebrospinal fluid, saliva . . . ). Sample
 the risk of cfDNA degradation and/or contamination with gDNA.
 extraction. Treatment with sodium bisulfite induces further
al DNA loss during purification steps. The choice of read length,
influence the coverage and the lower detection limit for DNA
www.sciencedirect.com
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ating procedures (SOP) for biofluid collection (choice of
anticoagulant, time interval between processing and col-
lection, storage temperature), processing (centrifugation
force and temperature, extraction method), quantification
and long-term storage need to be implemented to maxi-
mise the cfDNA recovery during extraction and to mini-
mise the levels of background noise that may come from
contaminating DNA [56].
Secondly, treatment of cfDNA with sodium bisulfite
results in further fragmentation and significant loss of
starting material during desulfonation and purification
procedures [57–59]. Even though the levels of cfDNA
are somewhat increased in cancer patients, the combina-
tion of minute amounts of tumour-specific methylated
DNA circulating in the excess of unmethylated ‘normal’
cfDNA, and bisulfite treatment may lead to reduced
complexity and stochastic sampling issues. In addition,
the limiting factor for variant detection in cfDNA meth-
ylation analysis by BS-seq is the background noise from
the incomplete bisulfite conversion, which might be
further reduced by optimisation of this step. Thus, effi-
cient protocols for cfDNA isolation from plasma and
bisulfite treatment are critical factors for the subsequent
generation of libraries of sufficient complexity and suc-
cessful analysis of sparse amounts of methylated DNA in
plasma.
Finally, standard BS-seq protocols, where adaptor tagging
is preceding the bisulfite conversion step, followed by
several gel purification steps resulting in a significant loss
of starting material, require micrograms of input DNA
and are not amenable for use on cfDNA. Other important
considerations for the BS-Seq EWAS study design that
are not the focus of this manuscript, are sample size,
sequencing depth, and the choice of analysis pipelines
that are described in greater detail elsewhere [32,60–65].
Methods for ultra-low input WGBS
Recently, new solutions have enabled a remarkable
reduction of the required starting material to allow gen-
eration of fairly complex libraries for whole-genome
(WGBS) bisulfite sequencing starting from tens of
nanograms to subnanogram quantities of DNA [52,66,
67,68].
Ultra-low input bisulfite sequencing became feasible by
incorporating bead-purification, single-tube library prep-
aration, and engineering different methods for library
construction based on: random priming of tagged adap-
ters to bisulfite converted ssDNA, post-bisulfite adaptor
tagging (PBAT) [69–71]; transposase-based library con-
struction – Tagmentation BS-seq (T-WGBS or Tn5mC-
seq) [72–74]; ssDNA adaptor ligation originally applied
to ancient DNA samples [75,76]; switching activity of
MMLV-RT enzyme to introduce both adapters in awww.sciencedirect.com single step – Capture and Amplification by Tailing
and Switching (CATS) [77]. These methods were suc-
cessfully applied for whole-genome methylation profil-
ing of single cells [78], maternal plasma for prenatal
diagnostics [68], and plasma from cancer patients
[50,51,79].
Targeted BS-seq of circulating cell-free
DNA
Preferably, EWAS would be performed using complete
methylome data. For the time being, however, the costs
associated with WGBS are still prohibitively high to allow
for high-throughput studies despite recent progress in
extracting more information from low depth-of-coverage
WGBS data [80].
Other approaches for medium- to high-coverage, targeted
bisulfite sequencing, rely on the non-specific enrichment
of CpG rich regions either by restriction-enzyme medi-
ated as in the case of reduced representation bisulfite
sequencing (RRBS), or target-specific enrichment. Modi-
fied RRBS methods were applied to study methylation in
small cell populations [81,82], and in single cells [83].
Although RRBS was successfully applied to laser cap-
tured FFPE samples [84], it is yet to be determined if is
amenable for use on highly fragmented cfDNA. In a
recent study, Wen et al. implemented an innovative
highly sensitive method for detection of thousands of
hypermethylated CpG islands in cfDNA, methylated
CpG tandems amplification and sequencing (MCTA-
Seq), to analyse a large cohort of tissue (n = 57) and
plasma samples(n = 94) from hepatocellular carcinoma
(HCC) patients (n = 36) and healthy controls (n = 55).
A panel of four genes specific for cancer detection
(RGS10, ST8SIA6, RUNX2 and VIM) was identified and
comparison between matched plasma and tissue samples
indicated that both the cancer and noncancerous tissues
contribute to elevation of the methylation markers in
plasma [85].
Conversely, target-specific enrichment might be carried
out using microdroplet PCR amplification (Raindance)
[86,87], ligation capture [88,89], bisulfite padlock probe
(BSPP) capture [90,91] or in-solution hybridization [92–
94]. To the best of our knowledge, these enrichment
methods were not yet applied to the genome-wide anal-
ysis of plasma cfDNA, due to the comparably high input
requirements (few hundred nanograms to few micro-
grams). Nonetheless, Miura et al. have recently combined
the PBAT protocol with in-solution hybridization using
Agilent SureSelect probes to perform targeted bisulfite
sequencing starting from only 30 ng of DNA [95]. With
continuing research in the field, we believe that target
enrichment in combination with aforementioned ultra-
low input methods for library preparation, may prove
highly suitable for future EWAS aimed at discovery of
novel cfDNA methylation biomarkers.Current Opinion in Genetics & Development 2017, 42:48–55
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EWAS performed on liquid biopsies represents a highly
promising and minimally invasive platform for discovery
of novel epigenetic biomarkers for early detection, prog-
nosis and treatment monitoring in cancer. Based on the
compelling advantages and progress discussed here, it is
not surprising to see both commercial and academic
initiatives being set up leveraging different aspects of
cell-free DNA analysis, including GrailBio (http://www.
grailbio.com/), leveraging ultra-deep sequencing, Can-
cerID (http://www.cancer-id.eu/), leveraging major pan-
European resources, C2c [96], leveraging integration with
whole-body imaging and UroMark, leveraging microdro-
plet technology [97], to name but a few. Following the
recent benchmarking of DNA methylation assays for
validating epigenetic biomarkers [98] and the develop-
ment of more sensitive methods overcoming the dis-
cussed technical limitations for genome-wide methyla-
tion analysis of cfDNA and ctDNA, we predict a surge in
EWAS-based studies utilizing liquid biopsies in the com-
ing years. Together with complementary approaches,
these studies will advance precision medicine for cancer
by facilitating the delivery of much-needed biomarkers
for transforming cancer health care.
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